Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned a consensus recommendation of “Hold” from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $110.17.
HALO has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Monday, November 9th. Zacks Research lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Morgan Stanley cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $105.00 to $109.00 in a report on Wednesday, November 11th. Finally, Leerink Partners downgraded Halozyme Therapeutics from an “outperform” rating to a “hold” rating and upped their price objective for the company from $110.00 to $117.00 in a research note on Friday, November 6th.
Read Our Latest Analysis on Halozyme Therapeutics
Halozyme Therapeutics Trading Down 1.8%
Shares of Halozyme Therapeutics stock opened at $91.35 on Thursday. The firm has a market cap of $10.41 billion, a PE ratio of 23.24, a P/E/G ratio of 0.34 and a beta of 0.92. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60. The stock has a fifty day moving average price of $113.21 and a 200-day moving average price of $86.03.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.09. The company had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The firm’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. Equities research analysts anticipate that Halozyme Therapeutics will post 8.34 EPS for the current year.
Latest Halozyme Therapeutics News
These are some of the HALO news items that stood out recently:
- Positive Sentiment: HC Wainwright reaffirmed its buy rating and set a $130 price target, suggesting substantial upside from the cited share price. HC Wainwright ratings
- Neutral Sentiment: JPMorgan raised its target to $81 from $79 but maintained a neutral rating; the new target is below the cited share price, signaling a more cautious view. JPMorgan ratings
- Negative Sentiment: A German court overturned the preliminary injunction that had blocked Merck from offering its subcutaneous Keytruda product in Germany. Halozyme says it will pursue a permanent patent case, but the ruling removes an immediate barrier to Merck’s launch and adds uncertainty to the dispute’s potential commercial impact. Report on German court ruling
Insiders Place Their Bets
In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $75,534,196.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This trade represents a 24.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 149,226 shares of company stock worth $15,744,643 in the last ninety days. Insiders own 2.50% of the company’s stock.
Hedge Funds Weigh In On Halozyme Therapeutics
Large investors have recently modified their holdings of the business. Hilton Head Capital Partners LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $33,000. CoreCap Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares during the period. MidFirst Bank bought a new position in shares of Halozyme Therapeutics in the second quarter worth $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $28,000. Finally, Quantbot Technologies LP bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
See Also
- Five stocks we like better than Halozyme Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
